Novo Nordisk invests DKK 380 million in its Kalundborg plant (6 May 2013)

Novo Nordisk invests DKK 380 million in its Kalundborg plant 

Bagsværd, 6 May 2013 – Novo Nordisk is investing an additional 380 million Danish kroner in its Kalundborg plant in Denmark. The project will create 50 new production and engineering jobs in Kalundborg, where Novo Nordisk currently employs more than 2,400 people.

The investment will be used to convert manufacturing capacity in an existing facility to allow for future production of semaglutide, a new treatment for type 2 diabetes being developed by Novo Nordisk. Semaglutide is a once-weekly GLP-1 analogue.

"The Kalundborg investment reaffirms our long-term commitment to creating and maintaining jobs in Denmark. This year alone Novo Nordisk has created 100 new jobs in Kalundborg, and we are constantly looking for talented and skilled people," says Per Valstorp, senior vice president, Product Supply, Novo Nordisk.

The converted plant is expected to be operational in the first quarter of 2014.

Other ongoing investment projects at Novo Nordisk in Denmark include a new domicile in Bagsværd and a new facility in Kalundborg for the production of biopharmaceuticals such as haemophilia medicine and growth hormone. The investments in these projects amount to 2 billion kroner.

About Novo Nordisk in Kalundborg

The plant in Kalundborg was established in 1969. Covering an area of 135 hectares – the equivalent of 270 football pitches – it is Novo Nordisk's largest manufacturing facility. Since 1999, Novo Nordisk has invested more than 7.5 billion kroner in the facility and, as a result, has created more than 1,000 new jobs. Around 23 million people with diabetes around the world are treated with diabetes care products made in Kalundborg.

For photos and b-roll supporting this press release, please visit novonordisk.com, where further information about the new domicile in Bagsværd and the biopharmaceuticals factory in Kalundborg is also available.

Headquartered in Denmark, Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. For more information, visit novonordisk.com.

 

Further information

Media:

 

 

Lars Pallisgaard

+45 4442 3730

[email protected]

Ken Inchausti (US)

+1 609 514 8316

[email protected]

 

 

 

Investors:

 

 

Kasper Roseeuw Poulsen

+45 4442 4303

[email protected]

Frank Daniel Mersebach

+45 4442 0604

[email protected]

Lars Borup Jacobsen

+45 3075 3479

[email protected]

Jannick Lindegaard (US)

+1 609 786 4575

[email protected]

 

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.